AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma

Table 2 Univariate Cox regression analyses of overall survival in the training cohort

Variable	HR	95%CI	P value
Gender (male vs female)	1.348	0.481-3.778	0.571
Age, years (> 55 vs ≤ 55)	0.996	0.538-1.845	0.990
BMI (> 22 vs ≤ 22)	0.923	0.495-1.721	0.802
Alcohol abuse (present vs absent)	0.783	0.407-1.507	0.465
HBsAg (positive vs negative)	1.029	0.434-2.443	0.948
Tumor size, cm (> 6 vs ≤ 6)	1.092	0.505-2.361	0.822
Tumor number (multiple vs single)	1.330	0.636-2.781	0.448
TBS (> 8 vs ≤ 8)	1.637	0.891-3.008	0.113
PVTT (present vs absent)	2.216	1.205-4.077	0.011
EHS (present vs absent)	1.382	0.708-2.700	0.339
Child stage (B vs A)	2.519	1.345-4.718	0.004
ECOG-PS (1-2 vs 0)	1.446	0.776-2.697	0.246
DBIL, μmol/L (> 7.3 vs ≤ 7.3)	3.629	1.875-7.025	< 0.001
ALP, U/L (> 120 vs ≤ 120)	2.892	1.544-5.416	0.001
AFP, ng/mL (> 100 vs ≤ 100)	2.798	1.451-5.395	0.002
NLR (> 2.5 vs ≤ 2.5)	3.363	1.606-7.044	0.001

BMI: Body mass index; HBsAg: Hepatitis B surface antigen; TBS: Tumor burden score; PVTT: Portal vein tumor thrombus; EHS: Extrahepatic spread; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; DBIL: Direct bilirubin; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; NLR: Neutrophil to lymphocyte ratio; HR: Hazard ratio; CI: Confidence interval.